New York, NY (PRWEB) March 22, 2014
A year after the U.S. Food and Drug Administration (FDA) publicly vowed to investigate the safety of a drug now involved in Byetta lawsuit (http://www.byettalawsuit.com/) filings, as well as several other Type 2 diabetes medications, court documents show more than 320 cases now pending in a litigation underway in California federal court, Bernstein Liebhard LLP reports.
According to its most recent update on March 13th, the U.S. Judicial Panel on Multidistrict Litigation (JPML) reveals that 325 lawsuits involving a class of medications referred to as incretin mimetics have now been filed in the U.S. District Court, Southern District of California. Many of the cases filed in this multidistrict litigation allege an association between Byetta and pancreatic cancer, and have been filed on behalf of individuals claiming to have developed this disease, as well as pancreatitis and thyroid cancer.
Court records indicate that 19 more cases, which may involve side effects caused by Byetta, Januvia and Victoza, among other Type 2 diabetes medications, have joined the California federal court proceeding since the Panel’s last update on February 19th. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
“Our Firm continues to hear from individuals on a regular basis who allegedly developed pancreatic cancer and pancreatitis after taking Byetta, so we are not surprised to see continued updates in the federal incretin mimetic litigation,” says Bernstein Liebhard LLP, a nationwide law firm representing clients injured by defective medical devices and drugs. Right now, the Firm is offering free and confidential case evaluations to individuals who may have been injured as a result of Byetta.
Byetta Lawsuit Allegations
All Type 2 diabetes lawsuits now pending in the U.S. District Court, Southern District of California were filed after the FDA publicly announced in March 2013 that it was investigating the possible dangers associated with Byetta and other drugs. The Drug Safety Communication was issued on March 14th, 2013 after the findings of a previously unpublished study showed an increased risk for precancerous cellular changes to the pancreas in users of incretin mimetics. So far, the FDA has been unable to conclude that such an association exists, but its review is ongoing.
Since last year, hundreds of lawsuits accusing drug manufacturers of failing to adequately warn about side effects that may stem from use of their products have been filed in California federal court. Court records from the beginning of 2014 show a substantial increase in the number of Januvia, Byetta pancreatic cancer claims, as well as lawsuits involving other drugs in the last few months alone, with dozens of new cases having joined the litigation since January. When the JPML updated its Case List on January 15th, 262 claims had been filed in the U.S. District Court, Southern District of California, compared to 325 that are now underway.
Diabetics who may have developed pancreatitis or pancreatic cancer after taking Byetta may be eligible to seek compensation from its manufacturer. Learn more about the alleged association between Byetta and pancreatic cancer by visiting Bernstein Liebhard LLP’s website. For a free case evaluation, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com